je.st
news
Lpath Reports Interim Data From Phase 2a Study For Anti-Cancer Drug, ASONEP
2014-07-30 10:19:09| drugdiscoveryonline Home Page
Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP™ is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all
Tags: data
study
reports
drug
Category:Biotechnology and Pharmaceuticals